Functional polymorphism of the myeloperoxidase gene in hypertensive nephrosclerosis dialysis patients

Hypertension Research

Volumn 30, Issue 12, 2007, Pages 1193-1198

  Doi, Kent ^a   Noiri, Eisei ^a   Maeda, Rui ^a   Nakao, Akihide ^a   Kobayashi, Shuzo ^b   Tokunaga, Katsushi ^a   Fujita, Toshiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

Author keywords

Dialysis; Flow cytometry; Hypertensive nephrosclerosis; Myeloperoxidase; Polymorphism

Indexed keywords

2 [6 (4' AMINO)PHENOXYL 3H XANTHEN 3 ON 9 YL]BENZOIC ACID; BENZOIC ACID DERIVATIVE; HYPOCHLORITE; MYELOPEROXIDASE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DNA POLYMORPHISM; FEMALE; FLOW CYTOMETRY; GENE FREQUENCY; GENOTYPE; HEMODIALYSIS; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NEPHROSCLEROSIS; NEUTROPHIL; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALLELES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEPHROSCLEROSIS; NEUTROPHILS; PEROXIDASE; POLYMORPHISM, SINGLE NUCLEOTIDE; REACTIVE OXYGEN SPECIES; RENAL DIALYSIS;

EID: 38749102807     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.1193     Document Type: Article

References (28)

1. Nicholls SJ, Hazen SL: Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 1-9.
2. Zhang R, Brennan ML, Fu X, et al: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286: 2136-2142.
3. Brennan ML, Anderson MM, Shih DM, et al: Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest 2001; 107: 419-430.
4. Takizawa S, Aratani Y, Fukuyama N, et al: Deficiency of myeloperoxidase increases infarct volume and nitrotyrosine formation in mouse brain. J Cereb Blood Flow Metab 2002; 22: 50-54.
5. Austin GE, Lam L, Zaki SR, et al: Sequence comparison of putative regulatory DNA of the 5′ flanking region of the myeloperoxidase gene in normal and leukemic bone marrow cells. Leukemia 1993; 7: 1445-1450.
6. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF: An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996; 271: 14412-14420.
7. Reynolds WF, Chang E, Douer D, Ball ED, Kanda V: An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood 1997; 90: 2730-2737.
8. Crawford FC, Freeman MJ, Schinka JA, et al: Association between Alzheimer's disease and a functional polymorphism in the myeloperoxidase gene. Exp Neurol 2001; 167: 456-459.
9. London SJ, Lehman TA, Taylor JA: Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 1997; 57: 5001-5003.
10. Asselbergs FW, Tervaert JW, Tio RA: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2004; 350: 516-518.
11. Pecoits-Filho R, Stenvinkel P, Marchlewska A, et al: A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl 2003; (84): S172-S176.
12. Nangaku M: Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17-25.
13. Kimura N, Yonemoto S, Machiguchi T, Li X, Kimura H, Yoshida H: Synthetic/ secreting and apoptotic phenotypes in renal biopsy tissues from hypertensive nephrosclerosis patients. Hypertens Res 2006; 29: 573-580.
14. Doi K, Doi H, Noiri E, Nakao A, Fujita T, Tokunaga K: High-throughput single nucleotide polymorphism typing by fluorescent single-strand conformation polymorphism analysis with capillary electrophoresis. Electrophoresis 2004; 25: 833-838.
15. Usui C, Shibata N, Ohnuma T, et al: No genetic association between the myeloperoxidase gene -463 polymorphism and estrogen receptor-alpha gene polymorphisms and Japanese sporadic Alzheimer's disease. Dement Geriatr Cogn Disord 2006; 21: 296-299.
16. Matsuo K, Hamajima N, Suzuki R, et al: No substantial difference in genotype frequencies of interleukin and myeloperoxidase polymorphisms between malignant lymphoma patients and non-cancer controls. Haematologica 2001; 86: 602-608.
17. Katsuda N, Hamajima N, Tamakoshi A, et al: Helicobacter pylori seropositivity and the myeloperoxidase G-463A polymorphism in combination with interleukin-1B C-31T in Japanese health checkup examinees. Jpn J Clin Oncol 2003; 33: 192-197.
18. Setsukinai K, Urano Y, Kakinuma K, Maejima JH, Nagano T: Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species. J Biol Chem 2003; 278: 3170-3175.
19. Saran M, Beck-Speier I, Fellerhoff B, Bauer G: Phagocytic killing of microorganisms by radical processes: consequences of the reaction of hydroxyl radicals with chloride yielding chlorine atoms. Free Radic Biol Med 1999; 26: 482-490.
20. Candeias LP, Patel KB, Stratford MR, Wardman P: Free hydroxyl radicals are formed on reaction between the neutrophil-derived species superoxide anion and hypochlorous acid. FEBS Lett 1993; 333: 151-153.
21. Zhang C, Yang J, Jacobs JD, Jennings LK: Interaction of myeloperoxidase with vascular NAD(P)H oxidase-derived reactive oxygen species in vasculature: implications for vascular diseases. Am J Physiol Heart Circ Physiol 2003; 285: H2563-H2572.
22. Clark RA, Klebanoff SJ: Chemotactic factor inactivation by the myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest 1979; 64: 913-920.
23. el-Hag A, Clark RA: Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol 1987; 139: 2406-2413.
24. McGrath MS, Kahn JO, Herndier BG: Development of WF10, a novel macrophage-regulating agent. Curr Opin Investig Drugs 2002; 3: 365-573.
25. Kemp E, Dieperink H, Horn T, et al: WF10 in xenotransplantation - a potential new approach. Transplant Proc 2000; 32: 1018-1019.
26. Anders HJ, Vielhauer V, Schlondorff D: Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int 2003; 63: 401-415.
27. Ohashi J, Yamamoto S, Tsuchiya N, et al: Comparison of statistical power between 2 * 2 allele frequency and allele positivity tables in case-control studies of complex disease genes. Ann Hum Genet 2001; 65: 197-206.
28. Iseki K, Ikemiya Y, Iseki C, Takishita S: Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003; 63: 1468-1474.